{"id":1179,"date":"2012-07-16T20:37:36","date_gmt":"2012-07-17T00:37:36","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=1179"},"modified":"2012-07-16T21:22:28","modified_gmt":"2012-07-17T01:22:28","slug":"chromadex-gets-a-supplemental-boost-from-stock-guru-cdxc","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/chromadex-gets-a-supplemental-boost-from-stock-guru-cdxc-1179","title":{"rendered":"Chromadex Gets A Supplemental Boost From Stock Guru (CDXC)"},"content":{"rendered":"

ChromaDex (OTC: CDXC), a natural products company, has gotten the attention of at least one world-class investor. Dr. Phillip Frost<\/a> known for his sale of drug maker IVAX to TEVA (NYSE: TEVA) for $7.6 billion in 2005 has been accumulating shares of ChromaDex according to a news story released this afternoon. In June, Frost added to his 19% stake by purchasing an additional 600,000 shares. \u00a0Frost\u2019s latest buy of ChromaDex came at price of $.065. Apparently Frost is not the only insider doing some buying. In the last 12 months, insiders have registered 29 buys to only one sale.<\/p>\n

Coincidentally, ChromaDex shares have climbed over 20% since the opening last Thursday when they traded for $0.65. The stock ended today at a price of $0.79 on volume of 1.4 million shares, which dwarfs the average daily volume over the last three months of 248,000. \u00a0Shares of ChromaDex started the morning trading for $0.77. Both the high ($0.82) and the low ($0.751) were reached in the first 30 minutes of trading in the new week. The stock spent the rest of the day drifting before closing with a 6.8% gain.<\/p>\n

One year ago, ChromaDex stock established its 52-week high at a $1.84. Since March, share prices have bounced between an annual low of $0.44 and $0.75. One thing traders will contemplate tonight is whether the stock has finally started to shine after four months in the doldrums.<\/p>\n

The Irvine, California company supplies ingredients and phytochemical products and services to the dietary supplemental, food and beverage, cosmetic, and pharmaceutical industries. One product in the pipeline attracting excitement is a niacin supplement that could rival Niaspin produced byAbbot Laboratories (NYSE: ABT) . For the quarter ending in March 31, 2012, ChromaDex reported revenues of $7.3 million and a net loss per share of 15 cents.<\/p>\n

Headlines and commentary have been plentiful for ChromaDex over the last month. The following is a sample of some stories:<\/p>\n